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inclusion criteria. There were 25,986 patients receiving monotherapy and 18,818 receiving dual therapy. In the monotherapy group, 8,884 received ceftriaxone, 8,729 other cephalosporins, 3,918 macrolides, 3,130 penicillin and 1,335 quinolones. In the dual-therapy group, for their first antibiotic, 9,605 received ceftriaxone, 7,175 other cephalosporins, 1,420 penicillins and 618 quinolones. All of the dual-therapy patients then received macrolides.
Study design
This was a cohort study that examined the patients' records from several hospitals (the exact number was not given) whose records were in a centralised (hospital claims-made) database (HBSI EXPLORE, Solucient, LLC). This was a non-randomised study. The patients were studied for 30 days.
Analysis of effectiveness
This was an observational study that accounted for all the patients in the analysis. The primary health outcomes were the length of hospital stay (LOS) and the 30-day mortality. The different therapy groups were described in terms of their age, gender, race and one of four risk factors (A to D, where A represented the lowest risk). Among the patients receiving monotherapy, those in the macrolides group were younger and more likely to be in the lower risk group. The patients in the different treatment groups were not shown to be comparable in terms of their age, gender, race and health status. However, the authors attempted to take differences in health status into account by categorising the patients according to risk when assessing the effectiveness of the different antibiotic therapies.
Effectiveness results
From the tabulated results for the monotherapy patients, the LOS was 4.99 (standard deviation, SD=4.19) for ceftriaxone, 5.82 (SD=4.80) for other cephalosporins, 5.04 (SD=4.12) for macrolides, 6.09 (SD=4.26) for penicillins and 6.71 (SD=5.78) for quinolones. The mortality rates were 6.31 (ceftriaxone), 5.11 (other cephalosporins), 2.19 (macrolides), 8.15 (penicillins) and 4.94 (quinolones), respectively.
It was reported that the patients in the macrolides group had the lowest mortality, (p<0.001), but they were younger and likely to be in a lower risk category. In the text it was also reported that patients in the ceftriaxone group had the shortest LOS. However, this was not consistent with the tabulated results.
From the tabulated results for the dual-therapy patients, the LOS was 4.98 (SD=3.51) for ceftriaxone, 5.60 (SD=3.80) for other cephalosporins, 6.08 (SD=3.82) for penicillins and 6.47 (SD=4.76) for quinolones. The mortality rates were 2.76 (ceftriaxone), 2.16 (other cephalosporins), 2.46 (penicillins) and 2.91 (quinolones), respectively.
The tabulated results comparing dual therapy with monotherapy for four antibiotics showed a lower mortality rate for dual therapy, which was statistically significant for all apart from the quinolones, (p<0001). A shorter LOS was found for ceftriaxone dual therapy, which was described as statistically significant, (this is hard to reconcile given that the numbers were so close). Non statistically significant reductions in LOS were shown for the other cephalosporins. The results for penicillins showed a non statistically significant increase in LOS.
When the outcomes were divided according to risk category, the tabulated results showed the following were statistically significant (p<0.0001) for dual therapy: ceftriaxones, groups B and C increased LOS while groups C and D showed lower mortality rates; other cephalosporins, group C showed a lower mortality rate; penicillins, group C showed a lower mortality rate.
When the patients were divided into those aged above and below 65 years, the tabulated results showed the following statistically significant differences between dual therapy and monotherapy:
for the younger age group, an increase in LOS and a reduction in the mortality rate with ceftriaxone;
